TCR gamma/delta Monoclonal Antibody (5A6.E9), FITC, Invitrogen™

Description

TCR2061 targets TCR Pan TCR gamma delta in FACS applications and shows reactivity with Human samples. The TCR2061 immunogen is pan TCR gamma delta. TCR2061 detects TCR Pan TCR gamma delta which has a predicted molecular weight of approximately 18 kDa.

TCR gamma/delta (T-cell receptor gamma/delta) are specialized T-cells in the immune system. The ability of T cell receptors (TCR) to discriminate foreign from self-peptides presented by major histocompatibility complex (MHC) class II molecules is essential for an effective adaptive immune response. TCR recognition of self-peptides has been linked to autoimmune disease. Mutant self-peptides have been associated with tumors. Engagement of TCRs by a family of bacterial toxins know as superantigens has been responsible for toxic shock syndrome. Autoantibodies to V beta segments of T cell receptors have been isolated from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The autoantibodies block TH1-mediated inflammatory auto-destructive reactions and are believed to be a method by which the immune system compensates for disease. Most human T cells express the TCR alpha-beta and either CD4 or CD8 molecule (single positive, SP). However, a small number of T cells lack both CD4 and CD8 (double negative, DN). Increased percentages of alpha-beta DN T cells have been identified in some autoimmune and immunodeficiency disorders. Gamma-delta T cells are primarily found within the epithelium. They show less TCR diversity and recognize antigens differently than alpha-beta T cells. Subsets of gamma-delta T cells have shown antitumor and immunoregulatory activity.